Hillstream BioPharma to Participate in Two Major Industry Conferences
Biotechnology company, Hillstream BioPharma (Nasdaq: HILS), will participate in two major industry conferences in April 2023.
The company will present at the 2023 BioNJ BioPartnering Conference which will take place from April 17-18, 2023 in Somerset, New Jersey. Hillstream’s management team will also attend the CPHI North America Conference being held April 25-27, 2023 in Philadelphia, Pennsylvania.
Highlights
- As part of its presentation, Hillstream will discuss recent operational highlights, and updates on its immuno-oncology pipeline candidates, including Its lead drug candidate HSB-1216 and the outlook for initiating a clinical study in the second half of 2023, and the company’s emerging immune-oncology pipeline led by HSB-3215, an anti-HER2 monoclonal antibody.
- CEO, Randy Milby will hold one-on-one meetings with analysts and qualified investors at both conferences.
- Earlier in 2023, Hillstream entered an exclusive option agreement with Applied Biomedical Science Institute to license technology to develop proprietary multi-format biologics against drug resistant cancers including HER2-positive metastatic breast cancer, gastric cancer, lung cancer and ovarian cancer.
About Hillstream BioPharma
Hillstream BioPharma, Inc. is a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis and immuno-oncology targeted novel biologics. Ferroptosis is an emerging new anti-cancer mechanism resulting in iron mediated cell death. The Company is on track to submit an investigational new drug application (IND) and initiate a clinical study for HSB-1216 as a potential treatment for drug resistant cancers in the second half of 2023. Hillstream’s immuno-oncology pipeline includes HSB-3215 and HSB-1940 Quatrabody™, an anti-PD-1 novel biologic which could be coated onto Quatramers. Hillstream’s Quatramer™ proprietary tumor targeting platform extends duration of action and minimizes off-target toxicity for biologics, mRNA, peptides, small molecules and other modalities in the tumor microenvironment.
